threonine has been researched along with bortezomib in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biggs, JR; Garcia, M; Kraft, AS; Peterson, LF; Zhang, DE; Zhang, Y | 1 |
| Morris, AP; Sellin, JH; Umar, S; Wang, Y | 1 |
| Ludwig, A; Meiners, S; Stangl, K; Stangl, V | 1 |
| Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H | 1 |
| Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C | 1 |
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Appel, A | 1 |
| Gallastegui, N; Groll, M | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Hiepe, F; Radbruch, A | 1 |
| Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J | 1 |
| Bourenkov, G; Chari, A; Henneberg, F; Mata, RA; Schneider, TR; Schrader, J; Stark, H; Tittmann, K | 1 |
| Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S | 1 |
| Antoniadi, G; Eleftheriadis, T; Liakopoulos, V; Pissas, G; Stefanidis, I | 1 |
| Hasinoff, BB; Patel, D | 1 |
| Hawkins, CJ; Patatsos, K; Shekhar, TM | 1 |
6 review(s) available for threonine and bortezomib
| Article | Year |
|---|---|
Proteasome inhibitors: poisons and remedies.
Topics: Binding Sites; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Threonine | 2008 |
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
Plasma cells as an innovative target in autoimmune disease with renal manifestations.
Topics: Autoantibodies; Autoimmune Diseases; B-Lymphocytes; Boronic Acids; Bortezomib; Glomerulonephritis; Humans; Immunologic Memory; Immunosuppressive Agents; Kidney Diseases; Lupus Nephritis; Oligopeptides; Peptides; Plasma Cells; Proteasome Inhibitors; Threonine | 2016 |
[Proteasome inhibitors in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine | 2015 |
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Drug Discovery; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Threonine | 2017 |
10 other study(ies) available for threonine and bortezomib
| Article | Year |
|---|---|
Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association.
Topics: Animals; Boronic Acids; Bortezomib; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Immunoprecipitation; Mice; Mice, Knockout; Mutation; Nuclear Matrix; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines; Serine; Threonine; Transcription Factors; Transcription, Genetic; Ubiquitin | 2005 |
Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.
Topics: Animals; Axin Protein; beta Catenin; Boronic Acids; Bortezomib; Casein Kinase 1 epsilon; Cell Nucleus; Citrobacter rodentium; Colon; Cyclic AMP Response Element-Binding Protein; Cytoskeleton; DNA; Enterobacteriaceae Infections; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperplasia; Immunoprecipitation; Intestinal Mucosa; Mice; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Protein Kinase C; Pyrazines; Repressor Proteins; Serine; TCF Transcription Factors; Threonine; Transcription Factor 7-Like 2 Protein | 2007 |
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays | 2008 |
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine | 2012 |
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Topics: Antineoplastic Agents; Biocatalysis; Boron Compounds; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Drug Design; Glycine; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Threonine | 2016 |
A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity.
Topics: Antibody-Dependent Cell Cytotoxicity; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Graft Rejection; Histocompatibility; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Isoantibodies; Kidney Transplantation; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Oligopeptides; Proteasome Inhibitors; Threonine | 2017 |
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Topics: Animals; Animals, Newborn; Boron Compounds; Boronic Acids; Bortezomib; Cardiotoxicity; Cell Survival; Dose-Response Relationship, Drug; Epoxy Compounds; Glycine; Humans; K562 Cells; Ketones; Kinetics; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Rats, Sprague-Dawley; Threonine | 2018 |
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bone Neoplasms; Boron Compounds; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Glycine; Humans; Oligopeptides; Osteosarcoma; Proteasome Inhibitors; Sulfonamides; Threonine | 2018 |